Research Article

Prevalence of Clinically Significant Extraosseous Findings on Unenhanced CT Portions of $^{18}$F-Fluoride PET/CT Bone Scans

Chao-Jung Chen and Shih-Ya Ma

Department of Nuclear Medicine, Yuan’s General Hospital, 162 Cheng-Kung 1st Road, Kaohsiung 802, Taiwan

Correspondence should be addressed to Chao-Jung Chen, chenchaojung1975@yahoo.com.tw

Received 13 June 2012; Accepted 24 August 2012

Academic Editors: A. Frenkel, P. Hartvig, and D. Morris

Copyright © 2012 C.-J. Chen and S.-Y. Ma. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. Due to the frequently interrupted supply of $^{99m}$Tc-methylene diphosphonate, the use of $^{18}$F-fluoride positron emission tomography (PET)/computed tomography (CT) has become more popular. The study aims to determine the percentage of extraosseous findings from the unenhanced CT portion of $^{18}$F-fluoride PET/CT scans.

Materials and Methods. We retrospectively collected $^{18}$F-fluoride PET/CT studies between March 2010 and February 2011. The unenhanced CT portions of $^{18}$F-fluoride PET/CT were reviewed for each patient. Significant extraosseous findings related to malignancy from the unenhanced CT were recorded.

Results. A total of 158 patients (110 females, 48 males) were included in the study. Clinically significant extraosseous findings from the unenhanced CT were found in 43 patients (27.2%). Previously unknown extraosseous findings were identified in 17 patients (10.8%) after a review of the $^{18}$F-fluoride PET/CT scan results. Most of the extraosseous findings were small pulmonary metastases or enlarged metastatic lymph nodes.

Conclusion. It is not rare to identify new clinically significant extraosseous findings from the unenhanced CT of $^{18}$F-fluoride PET/CT studies. Therefore the clinical management of patients may be altered by the results, and a careful review of the unenhanced CT portion of $^{18}$F-fluoride PET/CT is mandatory.

1. Introduction

$^{18}$F-fluoride is a tracer element for bone scintigraphy that was introduced by Blau and others in the early 1960s. It was approved for clinical use by the U.S. Food and Drug Administration in 1972. However, the relatively high energy of the 511-keV annihilation photons produced by the decay of $^{18}$F prohibited its widespread use in the era of Anger-type $\gamma$-cameras suitable for the 140-keV photons of $^{99m}$Tc. $^{99m}$Tc-methylene diphosphonate (MDP) was therefore the most suitable technique for whole-body surveys due to its wide availability and consistent low cost [1].

The successful development of positron emission tomography (PET)/computed tomography (CT) and the frequent interruption of $^{99m}$Tc-MDP supply have led to a renewed interest in the use of $^{18}$F-fluoride PET/CT to detect bone metastases in cancer patients. Although the CT portion of the scan is mainly used for anatomic localization and attenuation correction, the scan might contain valuable information not shown on the PET image. Clinically significant findings from the unenhanced CT portion of $^{18}$F-fluorodeoxyglucose (FDG) PET/CT and myocardial perfusion single photon emission computed tomography (SPECT)/CT have been discussed [2–4]. To our knowledge, no information currently exists on the utility of the unenhanced CT portion from $^{18}$F-fluoride PET/CT. The purpose of this study was to assess the prevalence of clinically significant extraosseous findings from the unenhanced CT portions of $^{18}$F-fluoride PET/CT.

2. Materials and Methods

The study retrospectively included patients with known or suspected malignancy that underwent $^{18}$F-fluoride PET/CT studies for the detection of bone metastasis either for staging or followup between March 2010 and February 2011. The study protocol was approved by the institutional review board.

2.1. $^{18}$F-Fluoride PET/CT. Each patient was given 370 MBq (10 mCi) of $^{18}$F-fluoride intravenously. Subsequently, an integrated PET/CT scanner (Biograph; Siemens AG, Berlin, Germany) was used to acquire full body images 1 h after...
injection. The emission data acquisition time per bed was 3 minutes. The 6-slice CT was acquired using the following scanning parameters: 130 kVp, 95 mA, PITCH: 1.5, slice thickness: 3 mm. No CT contrast agent was administered. Both PET and CT scans were performed for patients under shallow breathing. All patients placed their arms at their sides during the CT acquisition. The images were reconstructed with a standard ordered-subset expectation maximization algorithm.

2.2. CT Interpretation. Two experienced board-certified nuclear medicine physicians reviewed the unenhanced CT scans using soft tissue, lung, and bone window settings. All skeletal findings from the unenhanced CT were excluded. Extraosseous findings from the unenhanced CT were considered significant and recorded if they were suspected to be malignant. Other extraosseous findings not related with malignancy, such as renal stone, were judged as nonsignificant and excluded. The clinically significant extraosseous findings from the unenhanced CT of $^{18}$F-fluoride PET/CT were compared with the previous exams and separated into either previously known or unknown groups. All patients had comparisons with followup imaging studies to confirm the findings from the unenhanced CT of $^{18}$F-fluoride PET/CT and to check for the existence of any missed lesions.

3. Results

A total of 158 patients were recruited in the study. There were 110 female patients and 48 male patients. The average age was 57 years old (range: 31–84 years old). These patients had diverse malignancies including 92 breast cancers, 16 hepatocellular carcinomas (HCC), 9 lung cancers, 7 nasopharyngeal carcinomas, 4 buccal cancers, 4 colon cancers, 4 esophageal cancers, 4 prostate cancers, 4 tongue cancers, and 14 other forms of cancer.

43 patients (27.2%) demonstrated clinically significant extraosseous findings from the unenhanced CT of $^{18}$F-fluoride PET/CT. After excluding previously known cases, 17 patients (10.8%) showed clinically significant new extraosseous findings (Table 1). Small pulmonary metastases were identified in 10 patients (Figure 1). Enlarged metastatic lymph nodes were found in 6 patients (Figure 2). Incidental primary malignancies, including lung and breast cancer (Figure 3), were discovered in two patients.

Unenhanced CT from $^{18}$F-fluoride PET/CT was unable to identify HCC tumors in 9 of 16 patients with either primary or recurrent hepatic tumors detected with concurrent CT or magnetic resonance imaging (MRI). Further retrospective review of the CT results only identified obscure images.

4. Discussion

$^{18}$F-fluoride PET has been proven to be more useful than $^{99m}$Tc-MDP scintigraphy for detection of bone metastasis in a variety of malignancies [5, 6]. With the aid of CT, $^{18}$F-fluoride PET/CT is better than $^{18}$F-fluoride PET alone and is more accurate than $^{99m}$Tc-MDP scintigraphy when compared to SPECT/CT [7–9]. Although the original role of CT in $^{18}$F-fluoride PET/CT is for identifying anatomic landmarks, it also provides a large amount of diagnostic information. Our study showed that most extraosseous findings occurred in the lungs. Given that low dose CT without contrast enhancement has been used widely in lung cancer screening for many years [10, 11], it is not surprising that the unenhanced CT in the PET/CT can also detect pulmonary lesions. These previously unknown small pulmonary metastases detected by the unenhanced CT of PET/CT could influence the future clinical management of these patients. Chest X-rays which are routinely used for followup care in lung cancer patients are not efficient at detecting small pulmonary nodules. In patients with HCC, the followup abdominal CT only images the lower part of the lung. Furthermore, the use of an additional low-dose CT scan during maximal inspiration after a PET/CT scan...
Table 1: Clinically significant extraosseous findings on CT of 18F-fluoride PET/CT.

<table>
<thead>
<tr>
<th>Patient no.</th>
<th>Age (y)</th>
<th>Sex</th>
<th>Type of cancer</th>
<th>Incidental findings by unenhanced CT</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>54</td>
<td>F</td>
<td>Breast cancer</td>
<td>Chest wall recurrence</td>
</tr>
<tr>
<td>2</td>
<td>46</td>
<td>F</td>
<td>Breast cancer</td>
<td>Pulmonary metastases</td>
</tr>
<tr>
<td>3</td>
<td>71</td>
<td>F</td>
<td>Breast cancer</td>
<td>Pulmonary metastases</td>
</tr>
<tr>
<td>4</td>
<td>34</td>
<td>F</td>
<td>Breast cancer</td>
<td>Axillary metastatic lymph nodes</td>
</tr>
<tr>
<td>5</td>
<td>68</td>
<td>F</td>
<td>Breast cancer</td>
<td>Pulmonary metastases and axillary metastatic lymph nodes</td>
</tr>
<tr>
<td>6</td>
<td>34</td>
<td>F</td>
<td>Breast cancer</td>
<td>Axillary metastatic lymph nodes</td>
</tr>
<tr>
<td>7</td>
<td>47</td>
<td>F</td>
<td>Breast cancer</td>
<td>Axillary metastatic lymph nodes</td>
</tr>
<tr>
<td>8</td>
<td>50</td>
<td>F</td>
<td>Breast cancer</td>
<td>Pulmonary metastases</td>
</tr>
<tr>
<td>9</td>
<td>61</td>
<td>F</td>
<td>Hepatocellular carcinoma</td>
<td>Pulmonary metastases</td>
</tr>
<tr>
<td>10</td>
<td>68</td>
<td>M</td>
<td>Hepatocellular carcinoma</td>
<td>Pulmonary metastases</td>
</tr>
<tr>
<td>11</td>
<td>50</td>
<td>M</td>
<td>Hepatocellular carcinoma</td>
<td>Pulmonary metastases</td>
</tr>
<tr>
<td>12</td>
<td>48</td>
<td>M</td>
<td>Hepatocellular carcinoma</td>
<td>Pulmonary and adrenal metastases</td>
</tr>
<tr>
<td>13</td>
<td>51</td>
<td>M</td>
<td>Buccal cancer</td>
<td>Cervical metastatic lymph nodes</td>
</tr>
<tr>
<td>14</td>
<td>70</td>
<td>F</td>
<td>Colon cancer</td>
<td>Pulmonary metastases</td>
</tr>
<tr>
<td>15</td>
<td>59</td>
<td>F</td>
<td>Endometrical cancer</td>
<td>Primary breast cancer with axillary metastatic lymph nodes</td>
</tr>
<tr>
<td>16</td>
<td>36</td>
<td>F</td>
<td>Ovarian cancer</td>
<td>Metastatic tumor of abdominal wall</td>
</tr>
<tr>
<td>17</td>
<td>45</td>
<td>M</td>
<td>Tongue cancer</td>
<td>Primary lung cancer with ipsilateral pulmonary metastases</td>
</tr>
</tbody>
</table>

PET: positron emission tomography; CT: computed tomography.

Figure 3: Incidental right breast mass (a) arrow, 2.7 × 1.7 cm in size) and several right axillary lymph nodes (b) arrows, the largest one is 1.0 × 0.8 cm in size) in a 59-year-old female with history of endometrial cancer were found by followup unenhanced CT of 18F-fluoride PET/CT. The biopsy for the right breast tumor confirmed the presence of invasive ductal carcinoma.

has been suggested [12]. However, based on our experience, the unenhanced CT portion of 18F-fluoride PET/CT with shallow breathing can detect the same pulmonary lesions as conventional contrast enhanced chest CT. The second most common extraosseous findings identified in this study were enlarged metastatic lymph nodes. Based on these results, contrast enhancement is not necessary for detection of metastatic lymph nodes [13]. Careful CT image analysis makes identifying metastatic lymph nodes possible. Primary malignancies, including lung and breast cancer, were incidentally observed in two patients. These findings suggest the possibility of using unenhanced CT of 18F-fluoride PET/CT for early detection for primary malignancy. The above-mentioned clinically significant extraosseous findings from the unenhanced CT of 18F-fluoride PET/CT show that this test can be used to identify previously unknown malignancies, and these results urge further study. Identifying additional lesions using this technique may lead to changes in the therapeutic management of patients. Although unenhanced CT may provide diagnostic information, there are limitations to this test. Without contrast enhancement, the CT poorly detects lesions in the solid organs such as the liver [14]. In our study, no hepatic tumors were found using unenhanced CT of PET/CT. Solid organ lesions missed by CT could be addressed by using abdominal ultrasonography as a complementary tool. The addition of contrast enhancement in 18F-FDG PET/CT has been widely discussed and can contribute additional information [15]. Conversely, no studies on contrast enhancement have been conducted with the 18F-fluoride PET/CT because CT is
addition, regular followup for cancer patients commonly decrease due to the increasing availability of cyclotrons. In when 99mTc-MDP was unavailable. Therefore, a potential followup studies such as contrast enhanced CT, MRI, or 18F-fluoride PET/CT training [2, 3, 16, 17]. However, in our study no potentially visible lesions were missed in the unenhanced CT portion of 18F-fluoride PET/CT when compared with followup studies such as contrast enhanced CT, MRI, or 18F-FDG PET/CT. Moreover, most nuclear medicine physicians also review the unenhanced CT in their daily practice of analyzing 18F-FDG PET/CT. Nuclear medicine physicians are capable of interpreting the unenhanced CT portion of 18F-fluoride PET/CT [4].

The frequent shortages and uncertain future supply of 99Mo may be a potential crisis that reduces the consistent use of 99mTc-MDP bone scintigraphy. In contrast, the supply of 18F-fluoride is increasing because of its widespread use in cyclotrons. Although 18F-fluoride is currently more expensive than 99mTc-MDP, the price differential could decrease due to the increasing availability of cyclotrons. In addition, regular followup for cancer patients commonly includes basic tests such as chest X-ray and abdominal ultrasonography. 18F-fluoride PET/CT with contrast enhancement can provide information for the entire skeletal system. This information cannot easily be obtained with other radiological images and can reduce the cost associated with chest X-rays and abdominal ultrasonography. The CT of 18F-fluoride PET/CT can detect pulmonary nodules less than 1 cm in diameter, which are difficult to verify by chest X-ray, and has the ability to detect enlarged lymph nodes through a whole body survey. By using contrast enhancement, potential lesions in solid organs such as the liver may also be detected. Contrast enhanced CT may lead to the replacement of abdominal ultrasonography. In the future, contrast enhanced 18F-fluoride PET/CT may be used in the followup of cancer patients. However, further studies are needed to determine whether this approach is cost-effective.

5. Conclusion

According to our preliminary data, it is not uncommon to locate previously undetected, clinically significant, extraosseous findings using unenhanced CT in the 18F-fluoride PET/CT. These new findings may have a great impact on the therapeutic planning and treatment of patients. Routinely and carefully reviewing the unenhanced CT portion of 18F-fluoride PET/CT is necessary.

References


